Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
Relevant studies have suggested that the MAPK signaling pathway is an essential pathway for aerobic glycolysis in pancreatic cancer, and the expression of p38 (MAPK) in cells can affect the secretion of aerobic glycolysis products (including Lactate) (137, 138)
It was first approved as Egrifta in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, and it remains a prescription drug with a regulator-reviewed label, including a defined dose, defined contraindications, and required safety monitoring
concluded that chemotaxis is required for Agrobacterium tumefaciens for biofilm development 120
by Sandoz starting February 22, 2025
10.1007/s00223-019-00647-5 219
US$ 25.11
US$ 27.86
US$ 25.39
US$ 26.53
US$ 26.90
US$ 29.14
